Amir Mortazavi, MD
Academic Title: Professor in the College of Medicine
Research Program: Molecular Carcinogenesis and Chemoprevention
About Me
More info forAs a medical oncologist, I manage all types of genitourinary malignancies, such as prostate, testicular, kidney and male genitalia cancers, yet my primary focus is clinical bladder cancer care. I was rated in the top 10 percent of physicians in the nation for patient satisfaction in 2014, 2016 and 2017. I was first trained in medicine at the University of Tehran and later studied internal medicine at the University of Buffalo, where I also conducted research at the Roswell Park Memorial Cancer Institute. I currently serve as an assistant professor in the Department of Internal Medicine at The Ohio State University. As a member of the Molecular Carcinogenesis and Chemoprevention Program at the OSUCCC – James, my research focuses on epigenetic modifications and experimental therapeutics for genitourinary cancers. One of my recent research projects suggests that sorafenib, an oral multikinase inhibitor, could have off-target effects on cytokine-induced signal transduction in immune effector cells. I have co-authored many articles in well-respected publications, including Cancer Chemotherapy and Pharmacology, Journal of Immunology, Journal of Proteome Research and Journal of Magnetic Resonance Imaging. Additionally, I have collaborated with other specialists on studies of bladder cancer prevention with unconventional dietary and nutritional strategies. What I enjoy most about working at The James is the tremendous desire of my peers to work together to provide optimal care for patients. With our multidisciplinary approach — a combination of research, education and care — patients receive unparalleled treatment. This is a special place that provides the latest technology, knowledge and resources as we strive toward a cancer-free world.
Clinical Expertise
More info for- Bladder Cancer
- Kidney Cancers
- Testicular Cancers
- Prostate Cancers
- Urologic Cancers
- Urethral Cancers
- Penile Cancers
- Urogenital Cancers
Research Interests
More info for- Weight Loss
- Colorectal Neoplasms
- Neoplasms
- Urinary Bladder Neoplasms
- Carcinoma, Renal Cell
- Leukemia, Lymphocytic, Chronic, B-Cell
- Leukemia, Promyelocytic, Acute
- Anorexia
- Leukemia, Myeloid, Acute
Where I See Patients
More info forEducation & Training
More info forGraduate - Pharmacy
- Loma Linda University School Of Medicine
11175 Campus St, Loma Linda, CA
Fellowship - Hematology & Oncology
- Ohio State University Wexner Medical Center
700 Ackerman Rd, Columbus, OH
Internship - Internal Medicine
- SUNY at Buffalo-Emergency Medicine GME
100 High St, Buffalo, NY
Residency - Internal Medicine
- SUNY at Buffalo-Emergency Medicine GME
100 High St, Buffalo, NY
Medical School
- Tehran University of Medical Sciences
PO Box 14155-6447, Tehran
- Loma Linda University School Of Medicine
Academic Office & Contact Information
More info forAcademic Office:
Lincoln Tower 1335
1800 Cannon Dr
Columbus, Ohio 43210Phone:
614-293-2886Email:
Amir.Mortazavi@osumc.eduReviews
More info forPatient Satisfaction Review
The overall patient satisfaction rating is an average of all patient responses to the five questions gathered from the Outpatient Oncology survey, developed by Press Ganey Associates for use in oncology clinics across the country. On behalf of The James, Press Ganey administers the survey to patients who see our providers in an outpatient clinic office. For additional information about the patient satisfaction survey, please visit our
Patient Satisfaction Survey page The comments are submitted by patients and reflect their view and opinions. The comments are not endorsed by and do not necessarily reflect the views of The James.
Videos
More info forPublications
More info forJuly 2, 2024Final Results From a Phase I Trial and Expansion Cohorts of Cabozantinib and Nivolumab Alone or With Ipilimumab for Advanced/Metastatic Genitourinary Tumors.
Apolo AB, Girardi DM, Niglio SA, Nadal R, Kydd AR, Simon N, Ley L, Cordes LM, Chandran E, Steinberg SM, Lee S, Lee MJ, Rastogi S, Sato N, Cao L, Banday AR, Boudjadi S, Merino MJ, Toubaji A, Akbulut D, Redd B, Bagheri H, Costello R, Gurram S, Agarwal PK, Chalfin HJ, Valera V, Streicher H, Wright JJ, Sharon E, Figg WD, Parnes HL, Gulley JL, Saraiya B, Pal SK, Quinn D, Stein MN, Lara PN, Bottaro DP, Mortazavi A
J Clin Oncol
May 13, 2024Characterization of FOLH1 Expression in Renal Cell Carcinoma.
Ovruchesky E, Pan E, Guer M, Elliott A, Siva S, Ravi P, McGregor B, Bagrodia A, Derweesh I, Barata P, Heath EI, Antonarakis ES, Darabi S, Hoon DSB, Mortazavi A, Choueiri TK, Nabhan C, Wei S, McKay RR
Cancers (Basel)
February 29, 2024Diagnosis and management of gastric-type endocervical adenocarcinoma: A case report and review of the literature.
Chalif J, Kistenfeger Q, Fulton J, Morton M, DeVengencie I, Weldemichael W, Vazzano J, O'Malley DM, Chambers LM
Gynecol Oncol
February 1, 2024NCCN Guidelines® Insights: Kidney Cancer, Version 2.2024.
Motzer RJ, Jonasch E, Agarwal N, Alva A, Bagshaw H, Baine M, Beckermann K, Carlo MI, Choueiri TK, Costello BA, Derweesh IH, Desai A, Ged Y, George S, Gore JL, Gunn A, Haas N, Johnson M, Kapur P, King J, Kyriakopoulos C, Lam ET, Lara PN, Lau C, Lewis B, Madoff DC, Manley B, Michaelson MD, Mortazavi A, Ponsky L, Ramalingam S, Shuch B, Smith ZL, Sosman J, Sweis R, Zibelman M, Schonfeld R, Stein M, Gurski LA
J Natl Compr Canc Netw
January 12, 2024A Comprehensive Review of Immunotherapy Clinical Trials for Metastatic Urothelial Carcinoma: Immune Checkpoint Inhibitors Alone or in Combination, Novel Antibodies, Cellular Therapies, and Vaccines.
Patel DM, Mateen R, Qaddour N, Carrillo A, Verschraegen C, Yang Y, Li Z, Sundi D, Mortazavi A, Collier KA
Cancers (Basel)
December 22, 2023Emerging Immunotherapy Approaches for Advanced Clear Cell Renal Cell Carcinoma.
Meng L, Collier KA, Wang P, Li Z, Monk P, Mortazavi A, Hu Z, Spakowicz D, Zheng L, Yang Y
Cells
December 16, 2023A Phase 2 Study of Sitravatinib in Combination with Nivolumab in Patients with Advanced or Metastatic Urothelial Carcinoma.
Msaouel P, Sweis RF, Bupathi M, Heath E, Goodman OB, Hoimes CJ, Milowsky MI, Davis N, Kalebasty AR, Picus J, Shaffer D, Mao S, Adra N, Yorio J, Gandhi S, Grivas P, Siefker-Radtke A, Yang R, Latven L, Olson P, Chin CD, Der-Torossian H, Mortazavi A, Iyer G
Eur Urol Oncol
September 20, 2023Emerging Immunotherapy Approaches for Treating Prostate Cancer.
Meng L, Yang Y, Mortazavi A, Zhang J
Int J Mol Sci
April 24, 2023Outcomes of Second-Line Therapies in Patients With Metastatic de Novo and Treatment-Emergent Neuroendocrine Prostate Cancer: A Multi-Institutional Study.
Eule CJ, Hu J, Al-Saad S, Collier K, Boland P, Lewis AR, McKay RR, Narayan V, Bosse D, Mortazavi A, Rose TL, Costello BA, Bryce AH, Lam ET
Clin Genitourin Cancer
April 11, 2023Clinical guideline highlights for the hospitalist: Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy.
Chitnis SD, Mortazavi A
J Hosp Med
January 1, 2023A multicenter study assessing survival in patients with metastatic renal cell carcinoma receiving immune checkpoint inhibitor therapy with and without cytoreductive nephrectomy.
Gross EE, Li M, Yin M, Orcutt D, Hussey D, Trott E, Holt SK, Dwyer ER, Kramer J, Oliva K, Gore JL, Schade GR, Lin DW, Tykodi SS, Hall ET, Thompson JA, Parikh A, Yang Y, Collier KA, Miah A, Mori-Vogt S, Hinkley M, Mortazavi A, Monk P, Folefac E, Clinton SK, Psutka SP
Urol Oncol
January 1, 2023Effect of Enfortumab Vedotin Dose Adjustment on Efficacy in Metastatic Urothelial Carcinoma: A Retrospective Single-Center Experience .
Clennon A, Hinkley M, Nymberg K, Ledbetter L, Handley D, McLaughlin E, Mortazavi A, Collier KA
Cancer Manag Res
January 28, 2022Neoadjuvant Atezolizumab With Gemcitabine and Cisplatin in Patients With Muscle-Invasive Bladder Cancer: A Multicenter, Single-Arm, Phase II Trial.
Funt SA, Lattanzi M, Whiting K, Al-Ahmadie H, Quinlan C, Teo MY, Lee CH, Aggen D, Zimmerman D, McHugh D, Apollo A, Durdin TD, Truong H, Kamradt J, Khalil M, Lash B, Ostrovnaya I, McCoy AS, Hettich G, Regazzi A, Jihad M, Ratna N, Boswell A, Francese K, Yang Y, Folefac E, Herr HW, Donat SM, Pietzak E, Cha EK, Donahue TF, Goh AC, Huang WC, Bajorin DF, Iyer G, Bochner BH, Balar AV, Mortazavi A, Rosenberg JE
J Clin Oncol
January 14, 2022Cabozantinib Plus Nivolumab Phase I Expansion Study in Metastatic Urothelial Carcinoma Patients Refractory to Immune Checkpoint Inhibitor Therapy.
Girardi DM, Niglio SA, Mortazavi A, Nadal R, Lara P, Pal SK, Saraiya B, Cordes L, Ley L, Sierra Ortiz O, Cadena J, Diaz C, Bagheri H, Redd B, Steinberg SM, Costello R, Chan KS, Lee MJ, Lee S, Yu Y, Gurram S, Chalfin HJ, Valera V, Figg WD, Merino M, Toubaji A, Streicher H, Wright JJ, Sharon E, Parnes HL, Ning YM, Bottaro DP, Cao L, Trepel JB, Apolo AB
Clin Cancer Res
January 1, 2022Kidney Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology.
Motzer RJ, Jonasch E, Agarwal N, Alva A, Baine M, Beckermann K, Carlo MI, Choueiri TK, Costello BA, Derweesh IH, Desai A, Ged Y, George S, Gore JL, Haas N, Hancock SL, Kapur P, Kyriakopoulos C, Lam ET, Lara PN, Lau C, Lewis B, Madoff DC, Manley B, Michaelson MD, Mortazavi A, Nandagopal L, Plimack ER, Ponsky L, Ramalingam S, Shuch B, Smith ZL, Sosman J, Dwyer MA, Gurski LA, Motter A
J Natl Compr Canc Netw
December 24, 2021Management of adverse events associated with cabozantinib plus nivolumab in renal cell carcinoma: A review.
McGregor B, Mortazavi A, Cordes L, Salabao C, Vandlik S, Apolo AB
Cancer Treat Rev
October 7, 2021Population Pharmacokinetic Analysis from First-in-Human Data for HDAC Inhibitor, REC-2282 (AR-42), in Patients with Solid Tumors and Hematologic Malignancies: A Case Study for Evaluating Flat vs. Body Size Normalized Dosing.
Liva S, Chen M, Mortazavi A, Walker A, Wang J, Dittmar K, Hofmeister C, Coss CC, Phelps MA
Eur J Drug Metab Pharmacokinet
October 1, 2021Early phase clinical studies of AR-42, a histone deacetylase inhibitor, for neurofibromatosis type 2-associated vestibular schwannomas and meningiomas.
Welling DB, Collier KA, Burns SS, Oblinger JL, Shu E, Miles-Markley BA, Hofmeister CC, Makary MS, Slone HW, Blakeley JO, Mansouri SA, Neff BA, Jackler RK, Mortazavi A, Chang LS
Laryngoscope Investig Otolaryngol
August 26, 2021Effect of Cisplatin and Gemcitabine With or Without Berzosertib in Patients With Advanced Urothelial Carcinoma: A Phase 2 Randomized Clinical Trial.
Pal SK, Frankel PH, Mortazavi A, Milowsky M, Vaishampayan U, Parikh M, Lyou Y, Weng P, Parikh R, Teply B, Dreicer R, Emamekhoo H, Michaelson D, Hoimes C, Zhang T, Srinivas S, Kim WY, Cui Y, Newman E, Lara PN
JAMA Oncol
May 14, 2021Randomized Phase III Trial of Gemcitabine and Cisplatin With Bevacizumab or Placebo in Patients With Advanced Urothelial Carcinoma: Results of CALGB 90601 (Alliance).
Rosenberg JE, Ballman KA, Halabi S, Atherton PJ, Mortazavi A, Sweeney C, Stadler WM, Teply BA, Picus J, Tagawa ST, Katragadda S, Vaena D, Misleh J, Hoimes C, Plimack ER, Flaig TW, Dreicer R, Bajorin D, Hahn O, Small EJ, Morris MJ
J Clin Oncol
January 25, 2021A phase 1 trial of the histone deacetylase inhibitor AR-42 in patients with neurofibromatosis type 2-associated tumors and advanced solid malignancies.
Collier KA, Valencia H, Newton H, Hade EM, Sborov DW, Cavaliere R, Poi M, Phelps MA, Liva SG, Coss CC, Wang J, Khountham S, Monk P, Shapiro CL, Piekarz R, Hofmeister CC, Welling DB, Mortazavi A
Cancer Chemother Pharmacol
January 6, 2021Risk Factors for Emergency Room and Hospital Care Among Patients With Solid Tumors on Immune Checkpoint Inhibitor Therapy.
Parikh AB, Zhong X, Mellgard G, Qin Q, Patel VG, Wang B, Alerasool P, Garcia P, Leiter A, Gallagher EJ, Clinton S, Mortazavi A, Monk P, Folefac E, Yin M, Yang Y, Galsky M, Oh WK, Tsao CK
Am J Clin Oncol
December 1, 2020Circulating Tumor Cell Subtypes and T-cell Populations as Prognostic Biomarkers to Combination Immunotherapy in Metastatic Genitourinary Cancer Patients.
Chalfin HJ, Pramparo T, Mortazavi A, Niglio SA, Schonhoft JD, Jendrisak A, Chu YL, Richardson R, Krupa R, Anderson AKL, Wang Y, Dittamore R, Pal SK, Lara PN, Stein MN, Quinn DI, Steinberg SM, Cordes LM, Ley L, Mallek M, Sierra Ortiz O, Costello R, Cadena J, Diaz C, Gulley JL, Dahut W, Streicher H, Wright JJ, Trepel JB, Bottaro DP, Apolo AB
Clin Cancer Res
November 20, 2020Results of a multicenter, phase 2 study of nivolumab and ipilimumab for patients with advanced rare genitourinary malignancies.
McGregor BA, Campbell MT, Xie W, Farah S, Bilen MA, Schmidt AL, Sonpavde GP, Kilbridge KL, Choudhury AD, Mortazavi A, Shah AY, Venkatesan AM, Bubley GJ, Siefker-Radtke AO, McKay RR, Choueiri TK
Cancer
October 23, 2020Alterations of DNA damage response genes correlate with response and overall survival in anti-PD-1/PD-L1-treated advanced urothelial cancer.
Joshi M, Grivas P, Mortazavi A, Monk P, Clinton SK, Sue-Ann Woo M, Holder SL, Drabick JJ, Yin M
Cancer Med
September 11, 2020Phase I Study of Cabozantinib and Nivolumab Alone or With Ipilimumab for Advanced or Metastatic Urothelial Carcinoma and Other Genitourinary Tumors.
Apolo AB, Nadal R, Girardi DM, Niglio SA, Ley L, Cordes LM, Steinberg SM, Sierra Ortiz O, Cadena J, Diaz C, Mallek M, Davarpanah NN, Costello R, Trepel JB, Lee MJ, Merino MJ, Bagheri MH, Monk P, Figg WD, Gulley JL, Agarwal PK, Valera V, Chalfin HJ, Jones J, Streicher H, Wright JJ, Ning YM, Parnes HL, Dahut WL, Bottaro DP, Lara PN, Saraiya B, Pal SK, Stein MN, Mortazavi A
J Clin Oncol
September 1, 2020NCCN Guidelines Insights: Kidney Cancer, Version 1.2021.
Motzer RJ, Jonasch E, Boyle S, Carlo MI, Manley B, Agarwal N, Alva A, Beckermann K, Choueiri TK, Costello BA, Derweesh IH, Desai A, George S, Gore JL, Haas N, Hancock SL, Kyriakopoulos C, Lam ET, Lau C, Lewis B, Madoff DC, McCreery B, Michaelson MD, Mortazavi A, Nandagopal L, Pierorazio PM, Plimack ER, Ponsky L, Ramalingam S, Shuch B, Smith ZL, Somer B, Sosman J, Dwyer MA, Motter AD
J Natl Compr Canc Netw
August 5, 2020A randomized phase 2 trial of pembrolizumab versus pembrolizumab and acalabrutinib in patients with platinum-resistant metastatic urothelial cancer.
Zhang T, Harrison MR, O'Donnell PH, Alva AS, Hahn NM, Appleman LJ, Cetnar J, Burke JM, Fleming MT, Milowsky MI, Mortazavi A, Shore N, Sonpavde GP, Schmidt EV, Bitman B, Munugalavadla V, Izumi R, Patel P, Staats J, Chan C, Weinhold KJ, George DJ
Cancer
April 10, 2020Prognostic Value of DNA Damage Response Genomic Alterations in Relapsed/Advanced Urothelial Cancer.
Yin M, Grivas P, Wang QE, Mortazavi A, Emamekhoo H, Holder SL, Drabick JJ, Woo SA, Pal S, Vasekar M, Folefac E, Clinton S, Monk P, Joshi M
Oncologist
April 9, 2020Randomized Double-Blind Phase II Study of Maintenance Pembrolizumab Versus Placebo After First-Line Chemotherapy in Patients With Metastatic Urothelial Cancer.
Galsky MD, Mortazavi A, Milowsky MI, George S, Gupta S, Fleming MT, Dang LH, Geynisman DM, Walling R, Alter RS, Kassar M, Wang J, Gupta S, Davis N, Picus J, Philips G, Quinn DI, Haines GK, Hahn NM, Zhao Q, Yu M, Pal SK
J Clin Oncol
April 1, 2020Effects of a lifestyle intervention on body composition in prostate cancer patients on androgen deprivation therapy.
Chaplow ZL, Focht BC, Lucas AR, Grainger E, Simpson C, Buell J, Fairman CM, Thomas-Ahner JM, Bowman J, DeScenza VR, Monk JP, Mortazavi A, Clinton SK
JCSM Clin Rep
Consulting and Related Relationships
More info forAt The Ohio State University Wexner Medical Center, we support a faculty member’s research and consulting in collaboration with medical device, research and/or drug companies because a faculty member’s expertise can guide important advancements in the practice of medicine and improve patient care. In order to provide effective management of these relationships, the university requires annual disclosures from all faculty members with external interests related to their university responsibilities. As of 09/30/2024, Dr. Mortazavi has reported no relationships with companies or entities.
Patient Comments
Again, very uplifting
Never felt rushed. Ample time given for questions or concerns.
I am cancer free because of the OSU cancer program and Gods intervention also!
Over the past 8 years Dr. Mortizavi and his staff have become family. They really care.
Dr. Mortazavi and his staff are all more than excellent
Dr. Mortazavi's follow up was excellent. I have been 8 years cancer free. He answer all of our questions.
Again, Dr. Mortazavi was extremely detailed when explaining my medical condition and available treatment options. During our consultation, he conveyed a genuine sense of caring for my well-being.
Dr Mortazavi and nurse Ashley are the best
Have been a patient of Dr Mortazi for over ten years . His knowledge. Professionalism, and concern for me is outstanding.
Dr. Mortazavi and his team has always demonstrated patience and answered all my questions.
Dr. Mortazavi is very personable as well as knowledgeable. He is the best!
Dr. Mortazavi is an amazing doctor. I am so blessed to be under his care. He is brilliant, kind, caring, understanding and humble. He is an asset to The James in so many ways.
Doctor Mortazavi & his staff are wonderful caring people and my family & I very much appreciate all of them
Very caring and professional.
It couldn't be any better I am cured 6 years now!
Ivery satisfied
My experience has always been very good.
Dr Mortizavi and his team have become trusted professionals in my cancer treatment. I look forward to my quarterly interactions with them.
Excellent care from Dr. Mortazavi and staff. His care and treatments have undoubtedly extended my life with quality!
Everyone from nurse to dr was excellent and very patient. Dr listened to concerns, answered questions, provided advice, explained in detail course of action and why, understood hesitation, took the time needed to make us understand and feel confident in the next steps.
Both Pohar an Mortazavi ar fantastic
I've neither met nor heard of another Doctor I would choose for my care other than my Doctor!
Excellent
Dr. Mortazavi and his staff are amazing. They definitely are concerned about helping their patients. I am blessed to be treated by them.
I am blessed to receive such good care from a dedicated physician and staff at The James. I have full confidence in their professionalism working together me me to achieve the best possible outcome.
Very good doctors
Proactive
Dr Mortazavi and his staff are wonderful! He always takes time to answer my questions. I was referred to him and came up from Cincinnati for treatment. I recently moved to Illinois and still drive back to Columbus for checkups.
Good
Dr. Mortazavi was very professional, knowledgeable, understanding and compassionate. He spent a long time making sure all of our questions and concerns were addressed, as well as, explaining the next steps involved in curing my cancer.
Care providers are top notch people. Dr. Mortazavi and hiss staff are the BEST!!
Dr. Mortazavi provides care well above & beyond any level ever expected!